Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceutical Chemicals
South Korea’s SK to acquire Ampac Fine Chemicals
by Michael McCoy
July 14, 2018
| A version of this story appeared in
Volume 96, Issue 29
The South Korean conglomerate SK Holdings will acquire Ampac Fine Chemicals as part of its plan to become a top-tier pharmaceutical contract development and manufacturing firm. Owned by the private equity firm H.I.G. Capital, Ampac operates plants in California, Texas, and Virginia and is one of the largest U.S. producers of pharmaceutical chemicals. Its Virginia facility was once owned by the drugmaker Boehringer Ingelheim. SK has drug chemical operations in South Korea and last year acquired a Bristol-Myers Squibb plant in Ireland.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter